Table 2.
Histological diagnoses.
| Entity | Newly diagnosed lesion n (%) | Recurrence n (%) | Total n (%) | |
|---|---|---|---|---|
| Glioma | Glioblastoma, IDH wild type | 354 (29.2) | 243 (20.1) | 596 (49.2) |
| Midline glioma, H3K27M-mutated | 12 (1.0) | 3 (0.2) | 15 (1.2) | |
| Astrocytoma WHO grade 4, IDH-mutant | 4 (0.3) | 41 (3.4) | 45 (3.7) | |
| Astrocytoma WHO grade 3, IDH-mutant | 19 (1.6) | 89 (7.3) | 108 (8.9) | |
| Astrocytoma WHO grade 2, IDH-mutant | 34 (2.8) | 32 (2.6) | 66 (5.4) | |
| High-grade astrocytoma with piloid features | 3 (0.2) | 1 (0.1) | 4 (0.3) | |
| Oligodendroglioma WHO grade 3, IDH-mutant and 1p/19q-codeleted | 8 (0.7) | 68 (5.6) | 76 (6.3) | |
| Oligodendroglioma WHO grade 2, IDH-mutant and 1p/19q-codeleted | 37 (3.0) | 72 (5.9) | 109 (9.0) | |
| Ganglioglioma | 7 (0.6) | 4 (0.3) | 11 (0.9) | |
| Pilocytic astrocytoma | 11 (0.9) | 13 (1.1) | 24 (2.0) | |
| Pleiomorphic xanthoastrocytoma | 0 (0.0) | 1 (0.1) | 1 (0.1) | |
| Pleiomorphic astroglial tumor | 2 (0.2) | 0 (0.0) | 2 (0.2) | |
| Ependymoma | 1 (0.1) | 1 (0.1) | 2 (0.2) | |
| Anaplastic ependymoma | 2 (0.2) | 3 (0.2) | 5 (0.4) | |
| Other gliomas, not elsewhere classified (NEC) | Glioma (NEC) | 1 (0.1) | 0 (0.0) | 1 (0.1) |
| Glial tumor | 11 (0.9) | 1 (0.1) | 12 (1.0) | |
| Glioneural tumor | 7 (0.6) | 0 (0.0) | 7 (0.6) | |
| Neuroepithelial tumor | 7 (0.6) | 1 (0.1) | 8 (0.7) | |
| Other | Initially suspected glioma, diagnosis other than glioma | 41 (3.4) | 4 (0.3) | 45 (3.7) |
| Metastasis | 31 (2.6) | 2 (0.2) | 33 (2.7) | |
| Medulloblastoma | 3 (0.2) | 4 (0.3) | 7 (0.6) | |
| Meningioma | 6 (0.5) | 4 (0.3) | 10 (0.8) | |
| Neurocytoma | 3 (0.2) | 2 (0.2) | 5 (0.4) | |
| Germinoma | 6 (0.5) | 1 (0.1) | 7 (0.6) | |
| Other entities (pineocytoma, neurinoma, diffuse leptomeningeal glioneuronal tumor, papillary tumor of the pineal region, pineoblastoma, solitary fibrous tumor, craniopharyngioma, yolk sac tumor) | 7 (0.7) | 7 (0.7) | 14 (1.3) | |
| Total | 617 (50.8) | 597 (49.2) | 1,214 (100.0) | |